How GLP-1s are more than just weight-loss wonders – but not without risk
Not long ago, nobody was talking about GLP-1 receptor agonists. Most of us did not even know what…
LLY Stock: Foundayo Data Bolsters Weight-Loss Maintenance Case
Shares of Eli Lilly and Company NYSE: LLY, the world’s most valuable pharmaceutical stock, started 2026 in a…
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
By Bhanvi Satija and Chris Prentice LONDON/NEW YORK, May 21 (Reuters) – Lower prices for weight-loss pills from…
Could Eli Lilly’s Next Weight Loss Drug Waylay Wegovy — and Even Zap Zepbound?
After losing its market edge to Eli Lilly (NYSE: LLY) despite its first-mover advantage in weight-loss drugs, Novo…
Best Healthcare Stocks to Buy in 2026
Biogen (NASDAQ: BIIB) and Novo Nordisk (NYSE: NVO) represent different opportunities within the healthcare sector: One is a…
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
Novo Nordisk A/S Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders…
Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders
Novo Nordisk has shared new data that suggests a higher dose version of its blockbuster weight loss drug,…
Scoring 2 Million Prescriptions, Novo’s GLP-1 Pill Crushes Expectations
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built…
Oral Ozempic US Launch And Partnerships Test Novo Nordisk Valuation
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Novo Nordisk Expands GLP-1 Reach With Oral Ozempic And Pediatric Push
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Canada approves second generic version of Ozempic
OTTAWA, May 1 (Reuters) – The Canadian health regulator said on Friday that it had approved Canada-based Apotex’s…
Can Oral Ozempic and Label Expansions Revive NVO’s Near-Term Growth?
Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic…